INNOVATIONS in pharmacy
Medicaid patients are in poorer health, suffer a higher incidence of comorbidities and polypharmacy compared to the general population and may be at increased risk of Adverse Drug Reactions (ADRs). Using a previously collected database of Medicaid patients, this study will examine the association between estimated ADR incidence and drug adherence. The ADverse Drug Reaction/Event Screening System (ADDRESS) dataset provides incidence estimates top ADRs for each drug, which when combined provide a probabilistic incidence of ADRs (the drug's ADR "misery index"). Combining the ADR misery indexes for each drug on the patient's regimen provides the patient's overall ADR misery index. It will then be possible to explore associations between adherence and individual ADR incidence, total drug ADR incidence, and drug regimen ADR incidence.
Proposed Method: The ADDRESS database lists the incidence rates of all observed ADR symptom clusters for each drug, by synthesizing data on ADR incidence from the literature. For each patient, a list of all drugs taken will be extracted from the Medicaid dataset, and the Drug ADR misery for all of the patients' medications combined to derive total ADR misery, the probable ADR incidence for the patient' entire drug regimen.
The study will test if an association exists between individual drug adherence and drug ADR misery index, between total drug regimen ADR misery index and regimen adherence, if the strength of association between adherence and ADR misery will differ across drug indications, and if the association between adherence and ADR misery differs across different disease states.
Methods:
Patients with RA from the 2008-2012 Medicare Current Beneficiary Survey (MCBS) data with at least 2 Medicare Part D claims were included. Medication adherence was calculated as proportion of days covered (PDC) in a six-month period following date of first medication fill. Individuals with PDCs>=0.80 were considered adherent. Total OOP medication costs per patient were generated as a sum of imputed OOP costs per claim. Logistic regression was used to assess associations between adherence and class of drug and OOP costs.
Results: 542 patients met inclusion criteria. 85% were on cDMARDs. The proportion (95% confidence interval) of patients adherent to bDMARDs, 0.48, (0.40, 0.56), did not differ significantly from that for cDMARDs, 0.52, (0.47. 0.56) (p=0.1293). Patients on bDMARDs had significantly higher mean OOP costs ($922.86±1720) than patients on cDMARDs ($40.26±51.93). In univariate logistic regressions, there was no significant association between DMARD type (p=0.13) and adherence, or OOP costs (p=0.72) and adherence. In a multivariate logistic model, there was a trend towards bDMARDs having lower adherence (O.R.=0.6, 95% C.I. (0.351, 1.032)) than cDMARDs, but the difference was not significant (p=0.06).
Conclusion:
Adherence to DMARD therapy in patients with RA was relatively low at approximately one-half, and did not differ significantly between patients on biologic DMARDs (0.48±0.08) and those on conventional DMARDs (0.52±0.04), although patients on bDMARDs paid more out-of-pocket on an average as compared to patients on cDMARDs.
